Summary
Twelve patients with recurrent, metastatic, or inoperable gastric adenocarcinoma were enrolled in an Illinois Cancer Center phase II trial of amonafide (nafidimide), a novel compound that acts as a DNA intercalator. Treatment consisted of a 60-minute infusion of amonafide which was administered daily for 5 consecutive days every 3 weeks at a starting dose of 300 mg/m2/d. Doses were modified according to the grade of toxicity experienced and eight patients underwent dose escalations. All 12 patients were evaluable for response and toxicities were predominantly hematologic. Stabilization of disease for at least 28 days was observed in seven patients and disease progression was noted in five. The median survival was 7.4 months. Doses were sufficient to produce severe bone marrow toxicity in one-third of the patients treated. None of the patients responded to therapy, implying a true response rate less than.221. Based on the results of this study, amonafide showed no activity against gastric adenocarcinoma; however toxicity appeared acceptable at the 300 mg/m2/d x 5 consecutive days every 3 weeks dose and schedule.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Brana MF, Sanz AM: Synthesis and cytostatic activity of benz(de)iso-quinolin-l,3-diones: structure activity relationships. Eur J Med Chem-Chimica Therapeutica 3:207–212, 1981
Division of Cancer Treatment, National Cancer Institute: Annual report to the Food and Drug Administration. Nafidimide. NCS 308847, IND 25852, March 1986
Clinical Brochure: Nafidimide. National Cancer Institute. Bethesda, Maryland, 1984
Legha SS, Ring S, Raber M, Felder TB, Newman RA, Krakoff IH: Phase I clinical investigation of benziso-quinolinedione. Cancer Treatment Reports 71:1165–1169, 1987
Minutes of Phase I Working Group Meeting, November 1986. Investigational Drug Branch, National Cancer Institute. Bethesda, Maryland
Felder TB, McLean MA, Vestal ML, Lu K, Farquhar D, Legha SS, Shah R, Newman RA: Pharmacokinetics and metabolism of the antitumor drug amonafide (NCS-308847) in humans. Drug Metabolism and Disposition 15:773–778, 1987
Saez R, Craig JB, Kuhn JG, Weiss GR, Koeller J, Phillips J, Havlin K, Harman G, Hardy J, Melink TJ, Sarosy GA, Von Hoff DD: Phase I clinical investigation of amonafide. J Clin Oncol 7:1351–1358, 1989
Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47:207–214, 1981
Ratain MJ, Mick R, Berezin F, Janisch L, Schilsky RL, Williams SF, Smiddy J: Paradoxical relationship between acetylator phenotype and amonafide toxicity. Clin Pharm Ther 50:573–579, 1991
Ratain MJ, Mick R, Berezin F, Janisch L, Schilsky RL, Vogelzang NJ, Lane LB: Phase I study of amonafide dosing based on acetylator phenotype. Cancer Reso 52:2304–2308, 1993
Costanza ME, Korzun AH, Henderson IC, Rice AM, Wood WC, Norton L: Amonafide: an active agent in metastatic breast cancer (CALGB 8642). Proc Am Soc Clin Oncol 9:31, 1990
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mullane, M.R., Schilsky, R.L., Carroll, R.B. et al. Phase II study of amonafide in gastric adenocarcinoma. Invest New Drugs 12, 267–270 (1994). https://doi.org/10.1007/BF00873971
Issue Date:
DOI: https://doi.org/10.1007/BF00873971